Remdesivir an experimental viral infection drug makes COVID-19 severe patients recover within a week

Experimental Remdesivir viral infection drug boosts naval virus treatment

Remdesivir viral infection drug revolutionizes the treatment of the Naval virus. The experimental drug makes patients recover within a week of administration.
$ads={1}
The patients associated in a clinical trial of the drug have all had severe respiratory symptoms and fever, some were placed under ventilators but were able to leave the hospital after less than a week of treatment, STAT quoted the doctor leading the trial as saying.


“ The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” Dr Kathleen Mullane, an infectious disease specialist at the University of Chicago who is leading the clinical trial, said in the video.

“Most of our patients are severe and most of them are leaving at six days, so that tells us the duration of therapy doesn’t have to be 10 days,” she was quoted as saying.

“We understand the urgent need for a COVID-19 treatment and the resulting interest in data on our investigational antiviral drug remdesivir,” the company said in a statement to CNN